[Should we vaccinate patients with systemic lupus]Ewa Wiesik-Szewczyk
Klinika i Poliklinika Układowych Chorób Tkanki Łacznej w Warszawie, Instytut Reumatologii
Pol Merkur Lekarski 23:395-8. 2007
..In this review we would like to present data concerning safety and efficacy of vaccines in patients with SLE to help doctor to decide when vaccination is advisable and when should be avoided...
Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safetyEwa Wiesik-Szewczyk
Department of Systemic Connective Tissue Diseases, Institute of Rheumatology, Spartanska 1, 02 637, Warsaw, Poland
Clin Rheumatol 29:605-13. 2010
..05). The post-vaccination response was weaker in SLE patients compared to healthy subjects. Immunisation did not change underlying disease activity...
[Contemporaneous clinical picture of systemic sclerosis]Ewa Wiesik-Szewczyk
Instytut Reumatologii w Warszawie, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
Pol Merkur Lekarski 28:416-20. 2010
..Factors related to scleroderma renal crisis are presented, to provide clinical evaluation of patients at risk of this complication...
[Management of patients with systemic sclerosis]Ewa Wiesik-Szewczyk
Instytut Reumatologii, Klinika i Poliklinika Układowych Chorób Tkanki Łacznej
Pol Merkur Lekarski 28:421-3. 2010
..Despite intensive investigations disease modifying drug therapy is still unknown, but specific organ treatment increase survival and improve health related quality of life...
Target therapies in systemic lupus erythematosus: current state of the artE Wiesik-Szewczyk
Institute of Rheumatology, Department of Connective Tissue Diseases, Warsaw, Poland
Mini Rev Med Chem 10:956-65. 2010
..Future studies are likely to focus on specific organ involvement or treatment combinations with other immunosuppressive agents...
[Biological therapies of systemic lupus erythematosus]Marzena Olesinska
Instytut Reumatologii w Warszawie, Klinika Chorób Tkanki Lacznej
Pol Merkur Lekarski 20:371-3. 2006
..T cells and B cells activation, antibodies production, cytokines and complement components activation. Pathogenic basis of using these therapies, their safety and efficacy assessment have been presented...
[Evaluation of systemic lupus erythematosus activity during pregnancy]Marzena Olesinska
Klinika i Poliklinika Układowych Chorób Tkanki Lacznej, Instytut Reumatologii, Warszawa
Pol Arch Med Wewn 117:312-6. 2007
..Point values are ascribed to individual parameters depending on their intensity...